Loading clinical trials...
Loading clinical trials...
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER
Conditions
Interventions
PF-08052667
Sasanlimab
+2 more
Locations
47
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
AdventHealth Orlando
Orlando, Florida, United States
Moffitt Cancer Center at SouthShore
Ruskin, Florida, United States
Moffitt Cancer Center - International Plaza
Tampa, Florida, United States
Start Date
November 6, 2025
Primary Completion Date
January 29, 2030
Completion Date
January 28, 2033
Last Updated
April 21, 2026
NCT06510374
NCT06245603
NCT03945162
NCT06781879
NCT05126472
NCT07122414
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions